Stockreport

Cytek Biosciences Inc (CTKB) Reports Robust Revenue Growth and Positive Net Income in Q4 2023 [Yahoo! Finance]

Cytek Biosciences, Inc.  (CTKB) 
PDF Operating Expenses : Q4 operating expenses rose by 12% due to the Luminex acquisition and increased headcount. Net Income : Q4 net income improved to $6.3 million, up [Read more]